259 related articles for article (PubMed ID: 38194912)
1. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by TÂ cell immunotherapies.
Goddard ET; Linde MH; Srivastava S; Klug G; Shabaneh TB; Iannone S; Grzelak CA; Marsh S; Riggio AI; Shor RE; Linde IL; Guerrero M; Veatch JR; Snyder AG; Welm AL; Riddell SR; Ghajar CM
Cancer Cell; 2024 Jan; 42(1):119-134.e12. PubMed ID: 38194912
[TBL] [Abstract][Full Text] [Related]
2. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
3. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
[TBL] [Abstract][Full Text] [Related]
4. Genetic engineering of T cell specificity for immunotherapy of cancer.
Willemsen RA; Debets R; Chames P; Bolhuis RL
Hum Immunol; 2003 Jan; 64(1):56-68. PubMed ID: 12507815
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
Shor RE; Dai J; Lee SY; Pisarsky L; Matei I; Lucotti S; Lyden D; Bissell MJ; Ghajar CM
Mol Oncol; 2022 Jan; 16(1):130-147. PubMed ID: 34058066
[TBL] [Abstract][Full Text] [Related]
6. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR; Halladay T; Yang L
J Biomed Sci; 2024 Jan; 31(1):5. PubMed ID: 38217016
[TBL] [Abstract][Full Text] [Related]
7. Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.
Sauer S; Reed DR; Ihnat M; Hurst RE; Warshawsky D; Barkan D
Front Oncol; 2021; 11():659963. PubMed ID: 33987095
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
9. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
10. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer immunotherapy.
Zhou J; Zhong Y
Cell Mol Immunol; 2004 Aug; 1(4):247-55. PubMed ID: 16225767
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion by dormant disseminated cancer cells: A Fermi paradox?
Adam-Artigues A; Valencia Salazar LE; Aguirre-Ghiso JA
Cancer Cell; 2024 Jan; 42(1):13-15. PubMed ID: 38194913
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
15. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Aqbi HF; Coleman C; Zarei M; Manjili SH; Graham L; Koblinski J; Guo C; Xie Y; Guruli G; Bear HD; Idowu MO; Habibi M; Wang XY; Manjili MH
Breast Cancer Res; 2020 Oct; 22(1):116. PubMed ID: 33115528
[TBL] [Abstract][Full Text] [Related]
16. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
17. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
Sivaganesh V; Promi N; Maher S; Peethambaran B
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
[TBL] [Abstract][Full Text] [Related]
18. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Colonization: Escaping Immune Surveillance.
Schaller J; Agudo J
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207601
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
